Anxiety Disorders: Market Research Report
This report analyzes the worldwide markets for Anxiety Disorders in US$ Million.
The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World.
Annual estimates and forecasts are provided for the period 2009 through 2017.
Also, a six-year historic analysis is provided for these markets.
The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F.Hoffmann-la Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi, UCB SA, Valeant Pharmaceuticals International, and Watson Laboratories, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are primarily based upon search engine sources in the public domain.
The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World.
Annual estimates and forecasts are provided for the period 2009 through 2017.
Also, a six-year historic analysis is provided for these markets.
The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F.Hoffmann-la Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi, UCB SA, Valeant Pharmaceuticals International, and Watson Laboratories, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are primarily based upon search engine sources in the public domain.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.INDUSTRY OVERVIEW
Anxiety Disorders: A Prelude
Future Outlook – Market Challenged by Generics and Efficacy Issues
A Snapshot of the Global Market Opportunity
Prevalence of Specific Anxiety Disorders
Generalized Anxiety Disorder (GAD)
Obsessive-Compulsive Disorder (OCD)
Specific Phobias
Social Phobias
Panic Disorder
Post Traumatic Stress Disorder (PTSD)
Social Anxiety Disorder (SAD)
Anxiety Disorders Can Strike At Any Age
Shyness: A Form of Anxiety Disorder among Kids and Teenagers
Women - The Most Affected Lot with Anxiety
Patent Expiries – A Major Impediment to Market Growth
Patent Expiries of Select Leading Drugs Indicated for Anxiety Disorders
Leading Drugs and Indications for Anxiety Disorders
2.PHARMACOLOGICAL TREATMENT FOR ANXIETY DISORDERS
Pharmacological Treatment
Available Treatment for Anxiety Disorders – In a Nutshell
Antidepressants for Anxiety Disorders
Selective Serotonin Reuptake Inhibitors (SSRIs)
Zoloft (Sertraline)
Paxil (Paroxetine)
Prozac (Fluoxetine)
Cipralex/Lexapro (Escitalopram)
Competitive Scenario - Cymbalta Emerges as a Market Leader in Anti-Depressants Market
Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)
Cymbalta (Duloxetine)
Effexor (Venlafaxine)
Monoamine Oxidase Inhibitors (MAOIs)
Tricyclic and Tetracyclic Antidepressants (TCAs)
Other Antidepressants
Sedatives
Benzodiazepines (BZDs)
Other Medications
Obsessive Compulsive Disorder (OCD) Treatment
Generalized Anxiety Disorder (GAD) Treatment
Drugs Indicated for the Treatment of Generalized Anxiety Disorder (GAD)
Novel Therapies for GAD on the Anvil
Novel Compounds Under Investigation for Generalized Anxiety Disorder (GAD)
3.DRUG PIPELINE ANALYSIS
Select Anti-Anxiety Pipeline Drugs in Phase III Development Stage and Filed for Approval
Select Anti-Anxiety Pipeline Drugs in Phase II Development Stage
Select Anti-Anxiety Pipeline Drugs in Phase I Development Stage
4.NON-PHARMACOLOGICAL TREATMENT
Psychological Treatment
Cognitive Behavioral Therapy
Relaxation Techniques
Biofeedback
Hypnotherapy
Meditation
Natural Remedies for Treating Anxiety
Acupuncture
Other Treatment Options
Support Program
Changes in Lifestyle
5.ANXIETY DISORDERS – THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS
What is Anxiety Disorder?
Types of Anxiety Disorders
A Review of Anxiety Disorders
Generalized Anxiety Disorder (GAD)
Panic Disorder
Phobias
Agoraphobia
Social Phobia
Obsessive-Compulsive Disorder (OCD)
Symptoms, Obsessions and Compulsions of Obsessive-Compulsive Disorder
Particular Phobic Anxiety Disorder (PPAD)
Post-Traumatic Stress Disorder (PTSD)
Separation Anxiety Disorder (SAD)
Anxiety Disorders in Children
Anxiety Disorders in Teens
Causes and Factors for Anxiety Disorder
Symptoms
Diagnosis for Anxiety Disorders
6.PRODUCT APPROVALS AND LAUNCHES
Sun Pharma Receives FDA Approval to Commercialize Generic Cymbalta
Impax Receives Tentative FDA Approval for Generic Version of Cymbalta
Actavis Receives FDA Approval for Alprazolam
Sun Pharma Receives FDA Approval to Generic Version of Alprazolam
Bafna Pharmaceuticals Receives Approval for Anxiety Drug in UK
Coenzyme-A Technologies Introduces MODULATOR MATRIX I
Sun Pharma to Launch Generic Version of Venlafaxine
Eli Lilly Receives FDA Approval for Cymbalta for Treating GAD
Aurobindo Pharma Receives Tentative US FDA Approval for Escitalopram
Boehringer Ingelheim and Eli Lilly Obtain Approval for Cymbalta in Canada
Medtronic's Reclaim Deep Brain Stimulation Therapy Receives CE-Mark Approval
Otsuka Pharmaceutical and BMS Obtain FDA Approval for sNDA
Servier Obtains EMEA Approval for Valdoxan in Treating Major Depressive Episodes
Boehringer Ingelheim and Eli Lilly Receive EU Approval for Cymbalta in GAD
AstraZeneca Files for Approval of Seroquel XR for GAD in Europe
Glenmark Pharmaceuticals Launches Hydroxyzine Hydrochloride Tablets
Jazz Pharma Launches Once-A-Day LUVOX® CR Extended-Release Capsules
7.RECENT INDUSTRY ACTIVITY
Euthymics Acquires DOV Pharma
Abbott Acquires Solvay Pharmaceuticals
Pfizer Withdraws sNDA for Lyrica in Treating GAD
Eli Lilly Drags Sun Pharma to Court for Alleged Infringment of Cymbalta Patent
Pfizer Discontinues Late Stage Development of GAD Drug Candidate
Pacgen Biopharmaceuticals Acquires Xphase Pharmaceuticals
GSK Inks Agreement for Divesting Wellbutrin XL® Rights to Biovail International
Ligand Pharmaceuticals Acquires Neurogen
FDA Seeks Additional Information for Seroquel XR sNDA in GAD Treatment
AstraZeneca’s Seroquel XR™ Shows Improvement in GAD Symptoms
Synosia Therapeutics Begins Phase II Efficacy Trial for Rufinamide
Ambien CR® Improves Chronic Insomnia in Patients with Co-morbid GAD
AstraZeneca Files sNDA for Seroquel XR for Treating GAD
Bionomics Concludes GMP Synthesis of BNC210
OJSC Pharmstandard to Take Over Afobazol® Trademark
8.FOCUS ON SELECT GLOBAL PLAYERS
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (US)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Forest Laboratories, Inc. (US)
GlaxoSmithKline Plc. (UK)
H. Lundbeck A/S (Denmark)
Mylan, Inc. (US)
Neurocrine Biosciences, Inc. (US)
Pfizer, Inc. (US)
Ratiopharm (Germany)
Sanofi (France)
UCB SA (Belgium)
Valeant Pharmaceuticals International (US)
Watson Laboratories, Inc. (US)
9.GLOBAL MARKET PERSPECTIVE
III. MARKET
1.THE UNITED STATES
A. Market Analysis
Anxiety Disorders – A Major Health Burden
Prevalence of Anxiety Disorders
Product Approvals and Launches
Strategic Corporate Developments
Select Players
Bristol-Myers Squibb Company
Eli Lilly and Company
Forest Laboratories, Inc.
Mylan, Inc.
Neurocrine Biosciences, Inc.
Pfizer, Inc.
Valeant Pharmaceuticals International
Watson Laboratories, Inc.
B. Market Analytics
2.EUROPE
A. Market Analysis
Product Approval
B. Market Analytics
2A.FRANCE
A. Market Analysis
Clinical Trials/Product Approvals
Select Player
B. Market Analytics
2B.GERMANY
A. Market Analysis
Product Approval
Select Players
B. Market Analytics
2C.ITALY
A. Market Analysis
Select Player
Polifarma SpA
B. Market Analytics
2D.THE UNITED KINGDOM
A. Market Analysis
An Overview of the Market Opportunity
Product Approvals/Clinical Trials
Select Players
B. Market Analytics
2E.SPAIN
Market Analytics
2F.REST OF EUROPE
A. Market Analysis
Strategic Corporate Development
Select Players
B. Market Analytics
3.ASIA-PACIFIC
A. Market Analysis
Anxiety and Depression – A Major Debilitating Condition in Australia
Strategic Corporate Development
Select Player
B. Market Analytics
4.REST OF WORLD
A. Market Analysis
Product Approval
Select Player
Ranbaxy Egypt Ltd. (Egypt)
B. Market Analytics
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 63 (including Divisions/Subsidiaries - 85)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Africa
Middle East
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.INDUSTRY OVERVIEW
Anxiety Disorders: A Prelude
Future Outlook – Market Challenged by Generics and Efficacy Issues
A Snapshot of the Global Market Opportunity
Prevalence of Specific Anxiety Disorders
Generalized Anxiety Disorder (GAD)
Obsessive-Compulsive Disorder (OCD)
Specific Phobias
Social Phobias
Panic Disorder
Post Traumatic Stress Disorder (PTSD)
Social Anxiety Disorder (SAD)
Anxiety Disorders Can Strike At Any Age
Shyness: A Form of Anxiety Disorder among Kids and Teenagers
Table 1. Average Age of Onset for Select Anxiety Disorders (includes corresponding Graph/Chart)
Women - The Most Affected Lot with Anxiety
Table 2. Female to Male Ratio for Incidence of Anxiety Disorders by Type of Disorder (includes corresponding Graph/Chart)
Patent Expiries – A Major Impediment to Market Growth
Patent Expiries of Select Leading Drugs Indicated for Anxiety Disorders
Leading Drugs and Indications for Anxiety Disorders
2.PHARMACOLOGICAL TREATMENT FOR ANXIETY DISORDERS
Pharmacological Treatment
Available Treatment for Anxiety Disorders – In a Nutshell
Antidepressants for Anxiety Disorders
Selective Serotonin Reuptake Inhibitors (SSRIs)
Zoloft (Sertraline)
Paxil (Paroxetine)
Prozac (Fluoxetine)
Cipralex/Lexapro (Escitalopram)
Competitive Scenario - Cymbalta Emerges as a Market Leader in Anti-Depressants Market
Table 3. Select Leading Anti-Depressants indicated for Anxiety Disorders (2007-2009): Annual Revenues for Cymbalta, Lexapro, Paxil & Wellbutrin, Effexor, Zoloft, and Remeron in US$ Million (includes corresponding Graph/Chart)
Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)
Cymbalta (Duloxetine)
Effexor (Venlafaxine)
Monoamine Oxidase Inhibitors (MAOIs)
Tricyclic and Tetracyclic Antidepressants (TCAs)
Other Antidepressants
Sedatives
Benzodiazepines (BZDs)
Other Medications
Obsessive Compulsive Disorder (OCD) Treatment
Table 4. Dosing of Select Serotonin Reuptake Inhibitors in OCD Treatment
Generalized Anxiety Disorder (GAD) Treatment
Drugs Indicated for the Treatment of Generalized Anxiety Disorder (GAD)
Novel Therapies for GAD on the Anvil
Novel Compounds Under Investigation for Generalized Anxiety Disorder (GAD)
3.DRUG PIPELINE ANALYSIS
Select Anti-Anxiety Pipeline Drugs in Phase III Development Stage and Filed for Approval
Select Anti-Anxiety Pipeline Drugs in Phase II Development Stage
Select Anti-Anxiety Pipeline Drugs in Phase I Development Stage
4.NON-PHARMACOLOGICAL TREATMENT
Psychological Treatment
Cognitive Behavioral Therapy
Relaxation Techniques
Biofeedback
Hypnotherapy
Meditation
Natural Remedies for Treating Anxiety
Acupuncture
Other Treatment Options
Support Program
Changes in Lifestyle
5.ANXIETY DISORDERS – THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS
What is Anxiety Disorder?
Types of Anxiety Disorders
A Review of Anxiety Disorders
Generalized Anxiety Disorder (GAD)
Panic Disorder
Phobias
Agoraphobia
Social Phobia
Obsessive-Compulsive Disorder (OCD)
Symptoms, Obsessions and Compulsions of Obsessive-Compulsive Disorder
Particular Phobic Anxiety Disorder (PPAD)
Post-Traumatic Stress Disorder (PTSD)
Separation Anxiety Disorder (SAD)
Anxiety Disorders in Children
Anxiety Disorders in Teens
Causes and Factors for Anxiety Disorder
Symptoms
Diagnosis for Anxiety Disorders
6.PRODUCT APPROVALS AND LAUNCHES
Sun Pharma Receives FDA Approval to Commercialize Generic Cymbalta
Impax Receives Tentative FDA Approval for Generic Version of Cymbalta
Actavis Receives FDA Approval for Alprazolam
Sun Pharma Receives FDA Approval to Generic Version of Alprazolam
Bafna Pharmaceuticals Receives Approval for Anxiety Drug in UK
Coenzyme-A Technologies Introduces MODULATOR MATRIX I
Sun Pharma to Launch Generic Version of Venlafaxine
Eli Lilly Receives FDA Approval for Cymbalta for Treating GAD
Aurobindo Pharma Receives Tentative US FDA Approval for Escitalopram
Boehringer Ingelheim and Eli Lilly Obtain Approval for Cymbalta in Canada
Medtronic's Reclaim Deep Brain Stimulation Therapy Receives CE-Mark Approval
Otsuka Pharmaceutical and BMS Obtain FDA Approval for sNDA
Servier Obtains EMEA Approval for Valdoxan in Treating Major Depressive Episodes
Boehringer Ingelheim and Eli Lilly Receive EU Approval for Cymbalta in GAD
AstraZeneca Files for Approval of Seroquel XR for GAD in Europe
Glenmark Pharmaceuticals Launches Hydroxyzine Hydrochloride Tablets
Jazz Pharma Launches Once-A-Day LUVOX® CR Extended-Release Capsules
7.RECENT INDUSTRY ACTIVITY
Euthymics Acquires DOV Pharma
Abbott Acquires Solvay Pharmaceuticals
Pfizer Withdraws sNDA for Lyrica in Treating GAD
Eli Lilly Drags Sun Pharma to Court for Alleged Infringment of Cymbalta Patent
Pfizer Discontinues Late Stage Development of GAD Drug Candidate
Pacgen Biopharmaceuticals Acquires Xphase Pharmaceuticals
GSK Inks Agreement for Divesting Wellbutrin XL® Rights to Biovail International
Ligand Pharmaceuticals Acquires Neurogen
FDA Seeks Additional Information for Seroquel XR sNDA in GAD Treatment
AstraZeneca’s Seroquel XR™ Shows Improvement in GAD Symptoms
Synosia Therapeutics Begins Phase II Efficacy Trial for Rufinamide
Ambien CR® Improves Chronic Insomnia in Patients with Co-morbid GAD
AstraZeneca Files sNDA for Seroquel XR for Treating GAD
Bionomics Concludes GMP Synthesis of BNC210
OJSC Pharmstandard to Take Over Afobazol® Trademark
8.FOCUS ON SELECT GLOBAL PLAYERS
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (US)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Forest Laboratories, Inc. (US)
GlaxoSmithKline Plc. (UK)
H. Lundbeck A/S (Denmark)
Mylan, Inc. (US)
Neurocrine Biosciences, Inc. (US)
Pfizer, Inc. (US)
Ratiopharm (Germany)
Sanofi (France)
UCB SA (Belgium)
Valeant Pharmaceuticals International (US)
Watson Laboratories, Inc. (US)
9.GLOBAL MARKET PERSPECTIVE
Table 5. World Recent Past, Current and Future Analysis for Anxiety Disorders by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 6. World Historic Review for Anxiety Disorders by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 7. World 15-Year Perspective for Anxiety Disorders by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
III. MARKET
1.THE UNITED STATES
A. Market Analysis
Anxiety Disorders – A Major Health Burden
Prevalence of Anxiety Disorders
Table 8. US Prevalence of Anxiety Disorders by Type (includes corresponding Graph/Chart)
Product Approvals and Launches
Strategic Corporate Developments
Select Players
Bristol-Myers Squibb Company
Eli Lilly and Company
Forest Laboratories, Inc.
Mylan, Inc.
Neurocrine Biosciences, Inc.
Pfizer, Inc.
Valeant Pharmaceuticals International
Watson Laboratories, Inc.
B. Market Analytics
Table 9. The US Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 10. The US Historic Review for Anxiety Disorders Market With Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
2.EUROPE
A. Market Analysis
Product Approval
B. Market Analytics
Table 11. European Recent Past, Current & Future Analysis for Anxiety Disorders by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 12. European Historic Review for Anxiety Disorders Market by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 13. European 15-Year Perspective for Anxiety Disorders by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
2A.FRANCE
A. Market Analysis
Clinical Trials/Product Approvals
Select Player
B. Market Analytics
Table 14. French Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 15. French Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
2B.GERMANY
A. Market Analysis
Product Approval
Select Players
B. Market Analytics
Table 16. German Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 17. German Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
2C.ITALY
A. Market Analysis
Select Player
Polifarma SpA
B. Market Analytics
Table 18. Italian Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 19. Italian Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
2D.THE UNITED KINGDOM
A. Market Analysis
An Overview of the Market Opportunity
Table 20. Prevalence of Depression and Anxiety Disorders in the UK (2006): Percentage of Adult Population (16-75 Years) Affection by Condition (includes corresponding Graph/Chart)
Product Approvals/Clinical Trials
Select Players
B. Market Analytics
Table 21. The UK Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 22. The UK Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
2E.SPAIN
Market Analytics
Table 23. Spanish Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 24. Spanish Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
2F.REST OF EUROPE
A. Market Analysis
Strategic Corporate Development
Select Players
B. Market Analytics
Table 25. Rest of European Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 26. Rest of European Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
3.ASIA-PACIFIC
A. Market Analysis
Anxiety and Depression – A Major Debilitating Condition in Australia
Table 27. 12-Month Prevalence of Anxiety Disorders in Australia by Age Group (2006) (includes corresponding Graph/Chart)
Strategic Corporate Development
Select Player
B. Market Analytics
Table 28. Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 29. Asia-Pacific Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
4.REST OF WORLD
A. Market Analysis
Product Approval
Select Player
Ranbaxy Egypt Ltd. (Egypt)
B. Market Analytics
Table 30. Rest of World Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 31. Rest of World Historic Review for Anxiety Disorders Market with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 63 (including Divisions/Subsidiaries - 85)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Africa
Middle East
